Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowFRA:3IP -2.35%76 12-1 Month Momentum % is 419.73% as of Aug. 19, 2026. GuruFocus rates FRA:3IP with a GF Score™ of 76/100 and a GF Value™ of €35.28 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,016 Drug Manufacturers companies, Harrow ranks better than 80.61% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-19), Harrow's 12-1 Month Momentum % is 419.73%.
The industry rank for Harrow's 12-1 Month Momentum % or its related term are showing as below:
FRA:3IP's 12-1 Month Momentum % is ranked better than 80.61% of 1016
companies
in the Drug Manufacturers industry
Industry Median: -14.32
vs FRA:3IP: 419.73
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Harrow 12-1 Month Momentum % Related Terms
FRA:3IP vs XERS, PRGO, PAHC: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Harrow's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of 419.73% mean?
Harrow (FRA:3IP) has a 12-1 Month Momentum % of 419.73% as of Aug. 19, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Harrow and its competitors. According to the industry distribution chart, Harrow ranks #197 out of 1016 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is Harrow's 12-1 Month Momentum % too high?
Harrow's current 12-1 Month Momentum % is 419.73%. Based on the distribution chart, Harrow ranks #197 out of 1016 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Harrow has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's 12-1 Month Momentum % compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #197 out of 1016 companies for 12-1 Month Momentum %. This places Harrow in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Harrow and its competitors. Harrow's current 12-1 Month Momentum % is 419.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (FRA:3IP) is currently considered Fairly Valued. The stock's GF Value™ is €35.28, compared to a current price of €33.20 — trading 5.9% below its estimated fair value. The current 12-1 Month Momentum % is 419.73%. Harrow's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Harrow (FRA:3IP), the current 12-1 Month Momentum % is 419.73% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (FRA:3IP) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of €33.20 is trading 5.9% below its estimated GF Value™ of €35.28.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for FRA:3IP:
12-1 Month Momentum %: 419.73%
GF Value™: €35.28 vs. price of €33.20 (5.9% below fair value)
No single metric tells the full story. See the FRA:3IP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
76GF Score
Get the complete analysis for FRA:3IP
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3IP has been successfully added to your 
